Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zotatifin and Carboplatin in Advanced TNBC
NCT07783659Phase 1Not yet recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2027
- Primary completion
- Jun 2030
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zotatifin in triple negative breast cancer (TNBC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Adverse Events at 1 year. Planned start Feb 2027; status: not yet recruiting.
02
Drugs
zotatifin
03
Conditions
triple negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07783659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07783659.